← All trials
NCT06613997
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 15, 2025
- Primary completion
- Dec 31, 2026
- Completion date
- Dec 31, 2027
- First posted
- Sep 26, 2024
- Last posted
- Sep 26, 2024
- Enrollment
- 100
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of CongoLead sponsor
- Programme National de Lutte contre l'Onchocercose (PNLO)Official
- Government of FranceOfficial
- Government of FranceCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.